Clinical trials: Nasal Polyposis
- Condition Nasal Polyposis
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps(CRSwNP)
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
The objectives of this study are to describe the incidence of adverse events and the effectiveness of tezepelumab in patients receiving tezepelumab as indicated for severe asthma or CRSwNP in South Korea.
- Trial name
- Tezepelumab (NCT06998095)
- Volunteers
- 210 people
- Sponsor
- AstraZeneca
Nasal Polyps
Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)
The purpose of this study is to evaluate the safety and efficacy of Nasonex® (Mometasone Furoate Nasal Spray(MFNS)) in the treatment of nasal polyps in pediatric subjects between the ages of 6 and less than 18 years old.
- Trial name
- NCT00378378
- Testing
- Mometasone Furoate Nasal Spray (MFNS)
- Volunteers
- 127 people
- Sponsor
- Organon and Co
Chronic Rhinosinusitis With Nasal Polyps
A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients
This is a prospective, multicenter real-world observational study designed to describe post-operative outcomes, quality of life, disease control, recurrence-related characteristics, economic burden and post-operative treatment…
- Trial name
- PREDICT (NCT07446738)
- Testing
- Other: Routine Clinical Care for CRSwNP
- Where
- 21 sites in China
- Volunteers
- 146 people
- Sponsor
- AstraZeneca
Bilateral Nasal Polyposis
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a…
- Trial name
- NCT03747458
- Testing
- OPN-375
- Where
- 31 sites in United States, Argentina
- Volunteers
- 40 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis Without Nasal Polyps
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal administration of 186 µg of OPN-375 twice a day (BID) in adolescent subjects with…
- Trial name
- Re-Open 3 (NCT06850805)
- Testing
- OPN-375
- Where
- 24 sites in United States
- Volunteers
- 84 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
- Trial name
- NCT06338995
- Testing
- LY3650150, Standard therapy for INCS
- Where
- 202 sites in United States, Argentina and 18 more
- Volunteers
- 510 people
- Sponsor
- Eli Lilly and Company
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals